According to a press release, Trimel, a Canadian pharmaceutical company, is moving forward with clinical trials on Tefina, a proposed treatment for female anorgasmia . The testosterone-based treatment is delivered nasally, as "a bioadhesive 'no touch' intranasal low-dose gel formulation of testosterone."
I read about this through the New View Campaign, which reminds folks that this is only the most recent in a series of drugs taken too quickly through trials to the FDA, only to be turned back. In 2004 there was Intrinsa, a testosterone patch, in 2010 it was the unfortunately named Flibanserin, a pill that worked on the central nervous system, and now a nasal spray.
There isn't much public information about this new treatment, although it is promising to address a different problem than the previous drugs which were meant to treat hypoactive sexual desire disorder. Tefina isn't promising to make you want sex more, just to make it more likely that you'll have an orgasm, presumably when you are having sex that you want.
If you're like me and find too many problems with DSM diagnoses of sexual dysfunction, not to mention problems with gender in sex research, it's hard to get excited about these new drugs. And the news media don't add to a sense of confidence when they become nothing more than a method of participant recruitment, as this idiotic coverage from Australia demonstrates.
But the number of people who don't experience much sexual pleasure or satisfaction in their lives is nothing to sneeze at, and more generously and optimistically it's possible that there are relatively safe medications that could help people get unstuck from sexual difficulties enough to figure out what the actual blocks are.
Read More: Yahoo News - Trimel Receives Approval to Conduct Tefina Clinical Study in Canada.
|| Twitter | Newsletter Signup | Sexuality Forum ||